Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
May 07 2024 - 3:05PM
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the
“Company”), an eyecare technology company focused on developing and
commercializing innovative, interventional technologies that
elevate the standard of care, today announced it will present at
the upcoming Bank of America Healthcare Conference, in Las Vegas,
NV.
Sight Sciences’ management is scheduled to
present on Tuesday, May 14, 2024, at 8:15 am PT / 11:15 am ET.
Interested parties may access a live and archived webcast of the
fireside chat on the “Investors” section of the company’s website
at: investors.sightsciences.com.
About Sight Sciences Sight
Sciences is an eyecare technology company focused on developing and
commercializing innovative and interventional technologies intended
to transform care and improve patients' lives. Using minimally
invasive or non-invasive approaches to target the underlying causes
of the world's most prevalent eye diseases, Sight Sciences seeks to
create more effective treatment paradigms that enhance patient care
and supplant conventional outdated approaches. The Company's OMNI®
Surgical System is an implant-free glaucoma surgery technology (i)
indicated in the United States to reduce intraocular pressure in
adult patients with primary open-angle glaucoma; and (ii) CE Marked
for the catheterization and transluminal viscodilation of Schlemm’s
canal and the cutting of trabecular meshwork to reduce intraocular
pressure in adult patients with open-angle glaucoma. Glaucoma is
the world's leading cause of irreversible blindness. The Company's
TearCare® System technology is 510(k) cleared in the United States
for the application of localized heat therapy in adult patients
with evaporative dry eye disease due to meibomian gland dysfunction
(“MGD”) when used in conjunction with manual expression of the
meibomian glands, enabling clearance of gland obstructions by
physicians to address the leading cause of dry eye disease. The
Company's SION® Surgical Instrument is a manually operated device
available in the United States to be used in ophthalmic surgical
procedures to excise trabecular meshwork.
For more information, visit
http://www.sightsciences.com
Sight Sciences and TearCare are trademarks of
Sight Sciences registered in the United States. OMNI, OMNI ERGO,
and SION are trademarks of Sight Sciences registered in the United
States, European Union and other territories.
© 2024 Sight Sciences. All rights reserved.
Media contact:pr@SightSciences.com
Investor contact:Philip TaylorGilmartin
Group415.937.5406Investor.Relations@Sightsciences.com
Sight Sciences (NASDAQ:SGHT)
Historical Stock Chart
From Apr 2024 to May 2024
Sight Sciences (NASDAQ:SGHT)
Historical Stock Chart
From May 2023 to May 2024